| Document |
Document Title |
|
WO/2010/003319A1 |
The invention provides macrolide derivatives, the preparation and the use thereof. The macrolide derivatives of the present invention are hydrates of erythromycin salts, their formula is C37H67NO13·A·nH2O, n=1.0-11.0, A is selected fro...
|
|
WO/2009/156938A2 |
The present invention relates to an improved process for the preparation of 6,9-imino ether of formula (I) an intermediate used in preparation of Azithromycin. The present invention further provides a process for preparation of Azithromy...
|
|
WO/2009/146052A2 |
A process for the purification of sucralose in sucralose-containing feed streams is disclosed. The process includes multiple liquid-liquid extraction steps; optionally, a concentration step; multiple crystallization steps; optionally, a ...
|
|
WO/2009/139181A1 |
Disclosed is a 10a-azalide compound which is effective against a bacterium Haemophilus influenzae (an influenza bacterium) or an erythromycin-resistant bacterium (e.g., resistant pneumococcus or streptococcus) and has a novel structure. ...
|
|
WO/2009/137737A2 |
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit superior antibacterial properties, particularly against Haemophilus influenzae. The present inventi...
|
|
WO/2009/130189A1 |
Novel 2 ' -O, 3 ' -/V-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2 ' -O, 3 ' -/V-bridged 14- membered macrolides and to 2 ' - O, 3 ' -/V-bridged 15-membered azalide macrol...
|
|
WO/2009/128537A1 |
Disclosed is a heterocyclic compound which can be used as an antipsychotic agent having a broader therapeutic spectrum compared with known typical antipsychotic agents and known atypical antipsychotic agents, having few adverse side effe...
|
|
WO/2009/128421A1 |
Disclosed is a novel form of 3-(3-{4-[3-(β-D-glucopyranosyl-oxy)-5-isopropyl-1H-pyrazole
-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethyl-propi
onamide with improved storage stability. 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isoprop...
|
|
WO/2009/121495A1 |
Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.
|
|
WO/2009/106419A1 |
The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compou...
|
|
WO/2009/102876A1 |
The invention provides compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically in...
|
|
WO/2009/100165A2 |
Disclosed is a method for separating anthocyanins depleted in phenolic mixture content from fruits or vegetables feedstock containing anthocyanins and phenolic mixtures. The first step is to contact the feedstock with a cation-exchange r...
|
|
WO/2009/084612A1 |
Disclosed is a method for producing an eriocitrin-containing material, which comprises the steps of: extracting a citrus extract containing eriocitrin from a citrus fruit with an extraction solvent; and separating eriocitrin from the cit...
|
|
WO/2009/084482A1 |
Disclosed is a means for promoting the absorption of a sesamin component in the body. The absorption of a sesamin component in the body can be promoted by using the sesamin component in combination with a quercetin glycoside.
|
|
WO/2009/084531A1 |
The invention provides a novel form of 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4
-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropiona
mide with improved storage stability. Since bis[3-(3-{4-[3-(β-D-glucopyrano...
|
|
WO/2009/075923A2 |
The present invention discloses compounds of formula I, II or, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (formulas) which exhibit antibacterial properties. The present invention further relates to pharmaceutical ...
|
|
WO/2009/065287A1 |
The present invention provides a mangiferin calcium and its preparation and use. The mangiferin calcium can lower plasma insulin, glucose, lipid, and also can improve the solubility and oral bioavailability of mangiferin and increase ins...
|
|
WO/2009/064953A1 |
The invention provides methods utilizing bridged macrolide or tylosin derivatives for the treatment of patients with inflammatory bowel diseases. The methods of the invention provide for the administration to a patient of a therapeutical...
|
|
WO/2009/055557A1 |
Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.
|
|
WO/2009/053259A1 |
The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of...
|
|
WO/2009/049370A1 |
The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic...
|
|
WO/2009/046620A1 |
Provided is a method of preparing cycloastragenol monoglycoside CMG (cycloastragenol-6-O-beta-D-glucoside), which comprises the following steps of: a. using astragaloside IV or extracts of Radix Astragali by conventional method as materi...
|
|
WO/2009/047992A1 |
It is intended to provide a novel UDP-glucuronyl transferase and a polynucleotide encoding the same (for example, a polynucleotide containing a polynucleotide comprising one nucleotide sequence selected from the group consisting of a nuc...
|
|
WO/2009/043296A1 |
The invention discloses gambogic glycoside derivatives and analogs represented by formula I, the preparation and the application thereof, wherein the substituents R1-R12 are defined as in the description. The gambogic glycoside derivativ...
|
|
WO/2009/039177A1 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: formula (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp...
|
|
WO/2009/022009A1 |
The invention relates to a pharmaceutical composition according to claim 1 comprising a pyrazole-O-glucoside derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions sel...
|
|
WO/2009/023196A1 |
Provided are compounds of formula (III) useful for modulation of immune responses, compositions comprising the compounds, and methods of use of such compositions for treating diseases or disorders involving an immune response. In certain...
|
|
WO/2009/023191A2 |
The present invention includes a process involving a one-pot reaction for preparing erythromycin 9-oxime salt comprising: (a) reacting erythromycin thiocyanate with an ammonium source to obtain erythromycin free base; (b) oximating the C...
|
|
WO/2009/021163A2 |
Described herein are methods of improving the efficiency of gene transfer for a wide range of applications. Specifically provided are methods of increasing expression of an exogenous gene in a cell by contacting the cell with a vector co...
|
|
WO/2009/019868A1 |
Disclosed is a novel 10a-azalide compound crosslinked at position-10a and position-12, which is represented by the formula shown below and is effective against an influenza bacterium or an erythromycin-resistant bacterium (e.g., an eryth...
|
|
WO/2009/016142A1 |
The present invention relates to novel 2'-O-substituted 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives having antimalarial activity. More particularly, the invention relates to 2'-O-substituted-9-deoxo-9a-methyl-9a-aza-9a-hom...
|
|
WO/2009/015541A1 |
The present invention discloses novel polyene diesters of formula 1 and their preparation. The diesters are used as prodrugs by introducing diester group to polyene antibiotics, which exhibit antifungal or antiviral activity through rele...
|
|
WO/2009/013351A2 |
This invention relates to solvated and non-solvated crystalline forms of 20,23- dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from)such crystalline form...
|
|
WO/2009/009906A1 |
A method for producing one or more than one isoflavonoid compound in a plant is described. The method comprises providing a production plant comprising one or more than one nucleotide sequence encoding isoflavone glycosyltransferase oper...
|
|
WO/2009/007988A1 |
The present invention relates to process for the preparation of 6-O-methylerythromycin A 9-oxime by treating 6-O-methylerythromycin A with hydroxyl amine hydrochloride in the presence of a base and a solvent.
|
|
WO/2009/004322A2 |
The present invention provides a compound of formula (I') which is a nystatin derivative having an additional double bond present between C28 and C29 and which is further modified relative to nystatin at one or more of positions C5, C7, ...
|
|
WO/2008/157751A2 |
The present invention provides substituted imidazoheterocyclic compounds having the structure of Formula (I) Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formul...
|
|
WO/2008/148223A1 |
The present invention provides a novel method for the transduction and/or transfection of plant cells. Cell-penetrating peptides (CPPs) have been successfully employed as nanocarriers to deliver proteins and oligonucleotides to single pl...
|
|
WO/2008/143677A1 |
Stable solid, crystalline forms of elsamitrucin salts are provided that are useful in preparing anti-neoplastic parenteral formulations. Also provided are methods for treating neoplastic diseases in humans using parenteral formulations t...
|
|
WO/2008/138243A1 |
Provided is a preparation method of icaritin, comprising treating the icariin with β-glucosidase in ethanol-water solution, then obtaining the icaritin by centrifugation and recrystallization. Also provided is a preparation method of ic...
|
|
WO/2008/139965A1 |
Disclosed is a vitamin B6 derivative having photostability and also having both of a proper water-solubility and a proper lipid-solubility. Specifically, the vitamin B6 derivative is a compound represented by the general formula (I) or a...
|
|
WO/2008/136037A2 |
The method, object of the present invention, concerns the peracylation of oleuropein and its products of hydrolysis: The method makes use of the excellent properties as Lewis acid catalysts of halides and tryphilates of lanthanides (III)...
|
|
WO/2008/126752A1 |
A skin-lightening agent containing a novel skin-lightening ingredient as an active ingredient. The active ingredient comprises equol and/or an equol glycoside formed by bonding one or more glycosyl groups to one or more of the hydroxy gr...
|
|
WO/2008/125683A1 |
There are described a derivative of Vitamin E capable of binding with the fibres of a fabric and gradually releasing Vitamin E by contact with the skin, the aforesaid fibres and the fabrics and garments produced therewith.
|
|
WO/2008/119543A1 |
The invention relates to a polymorphous form of clarithromycin (form V) as well as the production and use thereof.
|
|
WO/2008/111020A2 |
The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or ...
|
|
WO/2008/110918A2 |
The invention relates to compounds of Formula (I) wherein R1, R2, and X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of Formula (I).
|
|
WO/2008/106224A1 |
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2008/106226A2 |
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2008/099368A1 |
The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or ...
|
